New drug discovery offers method to identify metabolic condition therapies
Drug-initiated activity metabolomics screening discovers the metabolite myristoylglycine, that converts white fat cells to brown fat cells.
List view / Grid view
Drug-initiated activity metabolomics screening discovers the metabolite myristoylglycine, that converts white fat cells to brown fat cells.
In mice, researchers have shown that δ-valerobetaine plays a role in neurocognitive ability, making the metabolite a target for age-related memory loss.
Dr Antal Szalay, CEO and Founder of Ultimate Medicine, explores how the analysis of omics data, especially metabolomics and proteomics, can provide researchers with vital insight that can inform the development of drugs for conditions associated with age.
A new study links tumour necrosis factor seen in rheumatoid arthritis with T cell dysfunction, potentially leading to new therapies.
An imaging technique identified emerging drugs that activate the STING protein to alter metabolic pathway activity in cancer cells.
Eran Blacher has won the NOSTER & Science Microbiome Prize for discovering the link between the microbiome and neurodegenerative diseases.
Researchers have used comparative metabologenomics to uncover what may be “silencing” bacteria to produce desirable compounds.
Bacterial metabolites showed an increase in the cytotoxic activity in immune cells that could potentially influence efficiency of tumour therapies.
Acetate was found to be involved in regulating complex microbes and could help trigger an immune response against harmful bacteria in mice.
Scientists have presented a new method for generating the metabolic profiles of cells which could answer questions on conditions such as cancer and liver disease.
A small molecule found in a cell-based ultra-high-throughput screening campaign was shown to treat diabetes in cells and mice.
Scientists have used imaging methods and machine learning to understand cellular metabolism at the single-cell level.
25 May 2021 | By Metabolon
Discover how metabolomics can support your biomarker strategy in drug development and clinical trials in this on-demand webinar.
A synthetically made glycopeptide biologic has shown promise as a treatment for obesity-related diseases in mice.
Researchers have shown that loss of Asc-1 function could help obese patients maintain a healthy metabolism.